Examples of Bempedoic Acid in a sentence
Bempedoic Acid, a new molecular entity, is an adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor with the proposed indication as an adjunct to diet and maximally tolerated statins therapy for the treatment of adults with HeFM or established ASCVD who require additional lowering of LDL-C.
Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins.
A Randomized, Double-Blind, Placebo- Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC- 1002) 180 mg/day as Add-on to Ezetimibe Therapy in Patients with Elevated LDL-C Protocol Date: 18 January 2017 Sponsor: Esperion Therapeutics, Inc.
Investigator’s Brochure, Bempedoic Acid (ETC-1002), v12.0, Release Date 07 December 2017.14.
SPONSOR’S SIGNATUREStudy Title: A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 mg + Ezetimibe 10 mg Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo Alone in Patients Treated with Maximally Tolerated Statin TherapyStudy Number: 1002FDC-053Final Date: 18 October 2017 This clinical study protocol was subject to critical review and has been approved by the Sponsor.
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
Co-Chair (along with Felicia Cohn), Program Committee, American Society of Bioethics and Humanities, 7th Annual Meeting.
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low- Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.
Investor Contact: Alex SchwartzEsperion 734-249-3386aschwartz@esperion.com Media Contact:Elliot Fox W2Opure 212-257-6724efox@purecommunications.com Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results ANN ARBOR, Mich., November 6, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the third quarter ended September 30, 2019.